M. WilliamAudehMDMS

Oncology • Sherman Oaks, CA

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Chief Medical Officer, Agendia Inc.

Join to view full profile

Dr. Audeh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Audeh's full profile

Already have an account?

Office
14816 OTSEGO ST
Sherman Oaks, CA 91403
Phone+1 310-849-0561

Summary

Chief Medical Officer, Agendia, Inc.
Breast Cancer Genomics

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1986 - 1989
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1982 - 1986
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 1983 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Top Doctors:LA Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Join now to see all

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Start of enrollment: 2014 Feb 25
Terminated
Phase 3
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Start of enrollment: 2014 Nov 20
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

19 citations
A breast cancer gene signature for indolent disease.
Leonie J. M. J. Delahaye, CA Drukker, Christa Dreezen, Anke T. Witteveen, Bob Chan
Breast Cancer Research and Treatment. 2017-04-27
122 citations
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
Ursula A. Matulonis, Richard T. Penson, Susan M. Domchek, Bella Kaufman, Ronnie Shapira-Frommer
Annals of Oncology. 2016-06-01
218 citations
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, Rita K. Schmutzler, M. William Audeh
Gynecologic Oncology. 2016-02-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member